Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: OncorMed

This article was originally published in The Gray Sheet

Executive Summary

OncorMed: Will begin offering BRCA2 genetic testing Aug. 1 for susceptibility to breast and ovarian cancer, the Gaithersburg, Maryland firm announces. Pricing for BRCA2 testing will be comparable to OncorMed's current BRCA1 gene test: $420 for "stage 1" testing, the portion of the gene most likely to carry a mutation; and $775 for "stage 2" testing. Combined testing for both genes is $500 and $800 for stage 1 and stage 2, respectively. As with BRCA1 testing, BRCA2 testing will be available to physicians and medical centers under protocols developed by in-house institutional review boards or under an OncorMed-developed protocol ("The Gray Sheet" Jan. 15, p. 4)...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT006436

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel